

CellaVision presents the Interim report for the second quarter of 2021, on July 20, at 11:00 CEST

CellaVision AB (publ) will publish the Interim report for the second quarter, on July 20, 2021 at 7:20 CEST.

The report will be available at www.cellavision.com

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CEST where Simon Østergaard, President & CEO, will present and comment the report.

The presentation will be in English via a conference call or audio webcast:
<https://tv.streamfabriken.com/cellavision-q2-2021>

Phone number for the conference:

SE: +46 8 50 558 359

UK: +44 33 33 009 270

US: +1 64 67 224 904

No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time to facilitate a timely start.

Contact

Adele Horn
Investor Relations & Corporate Communications Specialist
Direct: +46 (0) 722 065 088

About Us

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 18 local market support organizations covering more than 40 countries. In 2020, sales were SEK 471 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Attachments

[CellaVision presents the Interim report for the second quarter of 2021, on July 20, at 11:00 CEST](#)